SGEN Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SGEN from our risk checks.
Seagen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$228.74 |
52 Week High | US$228.96 |
52 Week Low | US$123.77 |
Beta | 0.32 |
11 Month Change | 7.86% |
3 Month Change | 9.76% |
1 Year Change | 76.48% |
33 Year Change | 13.72% |
5 Year Change | 336.44% |
Change since IPO | 2,672.61% |
Recent News & Updates
Recent updates
Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing
Dec 12A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)
Apr 17Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation
Mar 20An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued
Dec 09Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation
Oct 14Seagen: A Stellar Portfolio Anchor
Oct 04Seagen in licensing deal with Lava Therapeutics for cancer candidate
Sep 26Seagen ticks lower as management suggests it could look at acquisitions
Sep 14Merck's talks with Seagen said to hit obstacle over price - report
Aug 26Seagen falls as arbitrator rules in favor of Daiichi Sankyo
Aug 12Shareholder Returns
SGEN | US Biotechs | US Market | |
---|---|---|---|
7D | 4.5% | -1.3% | 1.2% |
1Y | 76.5% | 23.2% | 30.2% |
Return vs Industry: SGEN exceeded the US Biotechs industry which returned -0.9% over the past year.
Return vs Market: SGEN exceeded the US Market which returned 20.8% over the past year.
Price Volatility
SGEN volatility | |
---|---|
SGEN Average Weekly Movement | 1.8% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: SGEN's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 3,256 | David Epstein | www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
SGEN fundamental statistics | |
---|---|
Market cap | US$43.15b |
Earnings (TTM) | -US$750.22m |
Revenue (TTM) | US$2.30b |
18.8x
P/S Ratio-57.5x
P/E RatioIs SGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SGEN income statement (TTM) | |
---|---|
Revenue | US$2.30b |
Cost of Revenue | US$2.13b |
Gross Profit | US$171.59m |
Other Expenses | US$921.81m |
Earnings | -US$750.22m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.98 |
Gross Margin | 7.46% |
Net Profit Margin | -32.61% |
Debt/Equity Ratio | 0% |
How did SGEN perform over the long term?
See historical performance and comparison